NASDAQ:ARWR - Arrowhead Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$17.93 +0.32 (+1.82 %)
(As of 02/15/2019 04:00 PM ET)
Previous Close$17.61
Today's Range$17.54 - $17.93
52-Week Range$5.35 - $22.39
Volume99,631 shs
Average Volume1.77 million shs
Market Capitalization$1.69 billion
P/E Ratio-27.45
Dividend YieldN/A
Beta2.23
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company offers ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver disease related to alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. It is also involved in the development of ARO-HBV, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.; and Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Receive ARWR News and Ratings via Email

Sign-up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARWR
CUSIPN/A
Phone626-304-3400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.14 million
Book Value$1.82 per share

Profitability

Net Income$-54,450,000.00

Miscellaneous

Employees95
Market Cap$1.69 billion
OptionableOptionable

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) issued its quarterly earnings data on Thursday, February, 7th. The biotechnology company reported $0.13 earnings per share for the quarter, missing analysts' consensus estimates of $0.76 by $0.63. The biotechnology company earned $34.66 million during the quarter, compared to analyst estimates of $90.88 million. Arrowhead Pharmaceuticals had a negative return on equity of 24.23% and a negative net margin of 61.78%. View Arrowhead Pharmaceuticals' Earnings History.

When is Arrowhead Pharmaceuticals' next earnings date?

Arrowhead Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Arrowhead Pharmaceuticals.

What price target have analysts set for ARWR?

6 analysts have issued 1-year target prices for Arrowhead Pharmaceuticals' stock. Their forecasts range from $11.68 to $25.00. On average, they expect Arrowhead Pharmaceuticals' stock price to reach $21.3633 in the next twelve months. This suggests a possible upside of 19.8% from the stock's current price. View Analyst Price Targets for Arrowhead Pharmaceuticals.

What is the consensus analysts' recommendation for Arrowhead Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arrowhead Pharmaceuticals.

What are Wall Street analysts saying about Arrowhead Pharmaceuticals stock?

Here are some recent quotes from research analysts about Arrowhead Pharmaceuticals stock:
  • 1. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating and $24 PT on Arrowhead Pharmaceuticals, following release of late-breaker abstracts for the Liver Meeting (AASLD) being held on San Francisco. Additional data from Arrowhead’s lead programs in hepatitis B virus (HBV) and alpha-1 antitrypsin (AAT) were made available further supporting activity of both compounds in chronic HBV patients and healthy volunteers, respectively. We believe these initial data add readthrough going into the meeting and further underscore Arrowhead’s ability to establish a platform RNAi company." (10/11/2018)
  • 2. Chardan Capital analysts commented, "We believe that Arrowhead is positioned to achieve a number of significant milestones in 2018. The Company spent most of 2017 quietly regrouping following its announcement in November 2016 that it was discontinuing all of its clinical RNAi programs (ARC-520, ARC-521, and ARC-AAT), which use its dynamic polyconjugate (DPC) delivery technology. The decision to discontinue development of these programs was based on the substantial delays that would have occurred in order to further explore the cause of deaths in a non-clinical toxicology study in non-human primates. Arrowhead subsequently reduced its workforce by approximately 30%. In September 2017, the Company unveiled its new proprietary delivery technology they call Targeted RNAi Molecule (TRiM), along with a portfolio of newly named candidates. Arrowhead’s TRiM delivery technology leverages advances in RNA chemistry and targeting, to deliver a payload with increased potency." (2/19/2018)

Has Arrowhead Pharmaceuticals been receiving favorable news coverage?

News headlines about ARWR stock have trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arrowhead Pharmaceuticals earned a daily sentiment score of 1.1 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the company's share price in the near future.

Who are some of Arrowhead Pharmaceuticals' key competitors?

Who are Arrowhead Pharmaceuticals' key executives?

Arrowhead Pharmaceuticals' management team includes the folowing people:
  • Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 50)
  • Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 53)
  • Dr. Bruce D. Given, Chief Operating Officer (Age 65)
  • Mr. Patrick O'Brien, Gen. Counsel (Age 55)
  • Dr. Mark M. Davis, Founder and Founder & Director of Insert Therapeutics Inc & Calando

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.63%), First Manhattan Co. (5.45%), Fiera Capital Corp (1.67%), Northern Trust Corp (1.16%), Geode Capital Management LLC (1.06%) and Candriam Luxembourg S.C.A. (0.63%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.

Which major investors are selling Arrowhead Pharmaceuticals stock?

ARWR stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Perceptive Advisors LLC, Oak Ridge Investments LLC, Barclays PLC, D. E. Shaw & Co. Inc., First Manhattan Co., MetLife Investment Advisors LLC and Northern Trust Corp. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

Which major investors are buying Arrowhead Pharmaceuticals stock?

ARWR stock was bought by a variety of institutional investors in the last quarter, including Fiera Capital Corp, Bank of America Corp DE, New York State Common Retirement Fund, Hsbc Holdings PLC, 361 Capital LLC, First Trust Advisors LP, BlackRock Inc. and Candriam Luxembourg S.C.A.. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $17.83.

How big of a company is Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals has a market capitalization of $1.68 billion and generates $16.14 million in revenue each year. The biotechnology company earns $-54,450,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Arrowhead Pharmaceuticals employs 95 workers across the globe.

What is Arrowhead Pharmaceuticals' official website?

The official website for Arrowhead Pharmaceuticals is http://www.arrowheadpharma.com.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 225 SOUTH LAKE AVENUE SUITE 1050, PASADENA CA, 91101. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]


MarketBeat Community Rating for Arrowhead Pharmaceuticals (NASDAQ ARWR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  324 (Vote Outperform)
Underperform Votes:  230 (Vote Underperform)
Total Votes:  554
MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARWR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARWR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel